Relationships between PET and blood plasma biomarkers in corticobasal syndrome
Open Access
- 17 June 2024
- journal article
- research article
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (7) , 4765-4774
Abstract
INTRODUCTION: Corticobasal syndrome (CBS) can result from underlying Alzheimer's disease (AD) pathologies. Little is known about the utility of blood plasma metrics to predict positron emission tomography (PET) biomarker‐confirmed AD in CBS.METHODS: A cohort of eighteen CBS patients (8 amyloid beta [Aβ]+; 10 Aβ−) and 8 cognitively unimpaired (CU) individuals underwent PET imaging and plasma analysis. Plasma concentrations were compared using a Kruskal–Wallis test. Spearman correlations assessed relationships between plasma concentrations and PET uptake.RESULTS: CBS Aβ+ group showed a reduced Aβ42/40 ratio, with elevated phosphorylated tau (p‐tau)181, glial fibrillary acidic protein (GFAP), and neurofilament light (NfL) concentrations, while CBS Aβ− group only showed elevated NfL concentration compared to CU. Both p‐tau181 and GFAP were able to differentiate CBS Aβ− from CBS Aβ+ and showed positive associations with Aβ and tau PET uptake.DISCUSSION: This study supports use of plasma p‐tau181 and GFAP to detect AD in CBS. NfL shows potential as a non‐specific disease biomarker of CBS regardless of underlying pathology.Highlights: Plasma phosphorylated tau (p‐tau)181 and glial fibrillary acidic protein (GFAP) concentrations differentiate corticobasal syndrome (CBS) amyloid beta (Aβ)− from CBS Aβ+. Plasma neurofilament light concentrations are elevated in CBS Aβ− and Aβ+ compared to controls. Plasma p‐tau181 and GFAP concentrations were associated with Aβ and tau positron emission tomography (PET) uptake. Aβ42/40 ratio showed a negative correlation with Aβ PET uptake.Keywords
Funding Information
- National Institutes of Health (R01‐AG50603, R01‐NS089757, R01‐DC12519‐06)
This publication has 75 references indexed in Scilit:
- Association of plasma biomarkers with cognition, cognitive decline, and daily function across and within neurodegenerative diseases: Results from the Ontario Neurodegenerative Disease Research InitiativeAlzheimer's & Dementia, 2023
- Evaluation of Plasma Phosphorylated Tau217 for Differentiation Between Alzheimer Disease and Frontotemporal Lobar Degeneration Subtypes Among Patients With Corticobasal SyndromeJAMA Neurology, 2023
- Associations of amyloid and neurodegeneration plasma biomarkers with comorbiditiesAlzheimer's & Dementia, 2021
- Plasma p‐tau181, p‐tau217, and other blood‐based Alzheimer's disease biomarkers in a multi‐ethnic, community studyAlzheimer's & Dementia, 2021
- The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's diseaseAlzheimer's & Dementia, 2021
- Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal SyndromeJAMA Neurology, 2020
- Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid StatusJAMA Neurology, 2019
- Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without DementiaJAMA, 2019
- Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement DisordersJAMA Neurology, 2019
- Clinicopathological correlations in corticobasal degenerationAnnals of Neurology, 2011